Avrion Therapeutics is a spin-off from EPFL developing AAV-based precision gene therapies for neurological disorders. Based on 10+ years of research at the Brain Mind Institute, we design cell-type specific gene therapy vectors, and identify novel targets using a proprietary discovery engine.

Products, services, technology

Bicistronic AAV vector tailored to selectively express therapeutic genes in neurons & astrocytes, to maximize efficacy & reduce risks of side effects. Avrion further develops this vector technology with a potent discovery engine to identify innovative therapeutic targets for neurological disorders.

Cooperation possibilities

Our bicistronic gene therapy platform allows co-targeting of neurons and astrocytes from a single AAV. The company is working on its second generation cell-type specific vectors to target other glial cells of therapeutic interest. Collaborations around the use of our bicistronic platform are open.

Location

Gewerbestrasse 24, 4123 Allschwil, Switzerland

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2020
  • Number of employees in Switzerland
    1-9
Key business